Cellectis SA - CMVLF stock
OTC Symbol: CMVLF | OTC Tier: Pink Limited
About[edit]
Cellectis S.A. is a biotechnological company in the clinical stage that focuses on developing immuno-oncology products using gene-edited T-cells expressing chimeric antigen receptors to target and eliminate cancer cells, with a range of product candidates in development for various hematologic malignancies and solid tumors; the company has established strategic alliances and collaborations with other biotech firms, and it was founded in 1999, headquartered in Paris, France.[1]
Cellectis is a leading gene-editing company that was founded in 1999 by André Choulika, Philippe Duchateau, and Laurent Poirot. The company is headquartered in Paris, France. Cellectis is at the forefront of developing innovative gene-editing technologies that enable precise modifications of genes in cells.[2]
The company's core technology, known as TALEN® (Transcription Activator-Like Effector Nucleases), allows for targeted and precise editing of DNA sequences in various organisms, including human cells. This technology offers significant potential for therapeutic applications, particularly in the field of immuno-oncology and genetic disorders. Cellectis has been a pioneer in the development of CAR-T cell therapies, a groundbreaking approach in cancer treatment that involves modifying a patient's own immune cells to recognize and attack cancer cells more effectively. Their proprietary TALEN technology plays a critical role in creating these CAR-T therapies.[3]
One of Cellectis' major achievements was the development of UCART19, an investigational CAR-T therapy for the treatment of B-cell acute lymphoblastic leukemia (B-ALL). UCART19 became the world's first allogeneic, gene-edited CAR-T therapy to enter clinical trials.[3]
The company has also collaborated with other biotechnology and pharmaceutical companies to explore the potential of its gene-editing technologies in various therapeutic areas.[2]
